comparemela.com

Latest Breaking News On - Sarepta therapeutics company profile - Page 7 : comparemela.com

Tekla Capital Management LLC Has $39 37 Million Holdings in Sarepta Therapeutics, Inc (NASDAQ:SRPT)

Tekla Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 102.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 285,653 shares of the biotechnology company’s stock after purchasing an additional 144,694 shares during the […]

Sarepta Therapeutics (NASDAQ:SRPT) Given Buy Rating at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a note issued to investors on Thursday, Benzinga reports. They presently have a $185.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 72.40% […]

CTC Capital Management LLC Buys 3,100 Shares of Sarepta Therapeutics, Inc (NASDAQ:SRPT)

CTC Capital Management LLC Buys 3,100 Shares of Sarepta Therapeutics, Inc (NASDAQ:SRPT)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Sarepta Therapeutics (SRPT) Scheduled to Post Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) is scheduled to announce its earnings results after the market closes on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($2.03) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link. Sarepta Therapeutics (NASDAQ:SRPT […]

Sarepta Therapeutics (SRPT) Overweight Rating Reaffirmed at Morgan Stanley

Morgan Stanley reaffirmed their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report sent to investors on Friday, Benzinga reports. They currently have a $183.00 price target on the biotechnology company’s stock. Several other research analysts have also weighed in on SRPT. Cantor Fitzgerald dropped their price target on […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.